The NCT team is obsessed with the quality, accuracy, and integrity of your data. Our professionals are dedicated to the discovery of innovative therapies for central nervous system disorders.
Dr. Keefe is the Chief Executive Officer of NeuroCog Trials. In an effort to bring cutting-edge innovation and rigorous standards to industry trials collecting neurocognitive data, he founded NeuroCog Trials in 2005.
Dr. Keefe’s devotion to scientific integrity is extended throughout the company’s leadership and staff which is thoroughly exemplified in the services provided to clients. He is responsible for initiating, developing, and maintaining supportive relationships with key industry leaders and scientific advisors.
He is Professor of Psychiatry, Psychology and Neurosciences at Duke University Medical Center. His work for the past 25 years has focused on applying innovative strategies in neuroscience to measure human cognition. He has published over 220 peer-reviewed scientific papers on cognition, schizophrenia, dementia, and other CNS disorders. Dr. Keefe has had a leadership role for cognitive methods and coordinating center data review for several large NIMH studies including the CATIE, MATRICS, TURNS, and TENETS projects. He is Associate Editor for Psychological Medicine, and on the Editorial Board of Schizophrenia Bulletin, Schizophrenia Research, and Innovations in Clinical Neuroscience.
Dr. Keefe is a Fellow of the American College of Neuropsychopharmacology, and on the Scientific Board of the Brain and Behavior Research Foundation. He was President of the International Society for CNS Clinical Trials and Methodology in 2012 through 2014.
He graduated from Princeton University in 1980, and received his PhD in clinical psychology from NYU in 1990. He completed his clinical psychology internship at Yale University School of Medicine in 1990.
Ms. Gadigian is the president and co-founder of NeuroCog Trials. She brings extensive knowledge of finance and business from over 20 years of working with private investment firms and various industries. During her 12+ years at NeuroCog Trials, Ms. Gadigian has spearheaded the organization’s strategic growth and global expansion of services. Ms. Gadigian is responsible for jointly managing the human resources, financial operations, and directs the standard of excellence in operations and recruitment across new therapeutic areas in pharmaceutical development, assuring an atmosphere that recruits, retains, and supports quality staff and consultants.
Mr. Spiegel serves as the Chief Operating Officer. Mr. Spiegel brings to the company more than 16 years of experience in finance and consulting and has worked for companies in many industries including healthcare, business services and technology. Prior to joining NeuroCog Trials, he was a founding partner and Principal at Cypress Associates LLC, a New York based Investment Banking firm, where he was responsible for a broad range of transactions including mergers and acquisitions, restructurings, and equity offerings. Before joining Cypress, he was with CIBC World Markets contributing as an Investment Banking Analyst in the technology group.
Mr. Spiegel received his B.A. in Economics and Public Policy Studies from Duke University and holds the Chartered Financial Analyst® designation.
Dr. Saxby leads the strategic development of new products and services, drawing on a strong scientific background in clinical trials and computerized cognitive testing, and a successful track record of product and service innovation.
Dr. Saxby has worked in clinical trials for over 15 years. He joined a computerized cognitive test provider in a scientific role in 2004. After relocating to Chicago, IL, in 2009, he transitioned into business development, responsible for new clinical trial business with US clients. Most notably, Dr. Saxby led the development of Cambridge Cognition’s service offering for Human Abuse Liability trials, creating a new revenue stream for the company. More recently as Senior Director at ProPhase, Dr. Saxby has been involved in Rater Training and in-study surveillance methods for ensuring quality of Clinician-Reported Outcomes (ClinROs) in psychiatry and neurology.
Dr. Saxby obtained his BSc in Psychology and his PhD at Newcastle University, UK, and continues to hold a Visiting Researcher position at the Institute for Ageing, where he has published over 30 papers on a range of disorders including dementia, late-life depression, surgery and hypertension.
Dr. Atkins is an Experimental Psychologist with expertise in cognitive psychology, cognitive neuroscience and mental health research. Prior to attending graduate school, she worked as a Study Coordinator at Weil Medical College, Cornell University where she managed clinical trials for a wide range of CNS disorders including Alzheimer’s disease, Huntington’s disease, ALS, headache disorders and stroke.
Dr. Atkins received a B.A. in Psychology from Oberlin College and an interdisciplinary Master’s degree from the University of Chicago prior to earning her Ph.D. in Psychology from the University of Michigan in 2009. She completed post-doctoral training at the Center for Cognitive Neuroscience at Duke University.
Dr. Atkins’ past research has used cognitive testing in conjunction with functional neuroimaging techniques to examine the cognitive and neural mechanisms of memory distortion and executive functioning. She has received National Research Service Awards from both the National Institute of Mental Health (NIMH) and the National Institute on Aging (NIA), and has authored numerous peer-reviewed publications and presentations. She brings to NeuroCog Trials expertise in neurocognitive assessment, experimental methodology and the biological basis of behavior
Ms. Walker is an experienced Project Manager with expertise in direct patient interaction and both large academic and industry trials. She has been working in the mental health field since graduation and has 15 years experience working with schizophrenia and bipolar populations. For the past 10 years, she has worked at Duke University Medical Center and John Umstead Hospital doing research on neurocognition. Mrs. Walker has extensive experience with cognitive assessment and has supervised the collection of data and data quality for several domestic and international multi-site trials, including the collection of data for over 1600 patients in the CATIE schizophrenia and dementia trials. She has also helped develop several cognitive instruments, including the Brief Assessment of Cognition in Schizophrenia (BACS), the Schizophrenia Cognition Rating Scale (SCoRS) and the Cognitive Assessment Interview (CAI).
Mrs. Walker received her B.A. in Rehabilitation Therapy from the University of North Carolina at Chapel Hill in 1996 and received an A.D. in Nursing in 2005
As Senior Director of Program Development, Ms. Piunti serves as the primary point of contact for all contract and budget negotiations including project initiation, amendments and change orders. During her tenure at NeuroCog Trials, Mrs. Piunti has served as Project Lead on several Phase 2 and Phase 3 studies, with a special emphasis on international trials in Asia and South America. Mrs. Piunti received her B.A. in English from Siena College.
Mr. Baldwin serves as the Director of Quality Assurance. He has over 20 years of experience in clinical trial research. He started his career in Data Management and held various positions in Information Technology, Regulatory and Quality Assurance departments at Contract and Academic Research Organizations. Prior to joining NeuroCog Trials, he worked in the Quality Assurance department of a local pharmaceutical company for over 6 years and progressed into the position of Associate Director of QA. In his role at NeuroCog Trials, Mr. Baldwin oversees the development and maintenance of a Quality Assurance program for NeuroCog Trials that includes compliance, training, auditing, documentation and QA support of sponsor projects to insure adherence to global regulations that apply to the work that NeuroCog Trials completes for their partners.
Mr. Baldwin received his B.A. in English from North Carolina State University.
Dr. Stroescu is a board-certified clinical neuropsychologist with expertise in medical neuropsychology. He has extensive neurocognitive consultation and clinical assessment experience with dementia and a wide range of neurological disorders, in both in- and out-patient settings, as well as in clinical trials.
Prior to joining NeuroCog Trials Dr. Stroescu was a faculty neuropsychologist and assistant clinical professor at Barrow Neurological Institute in Phoenix, AZ. He obtained a B.A. in Psychology and Biology from Columbia College in Columbia, MO. He earned his M.S. and Ph.D. with a concentration in Neuropsychology from Saint Louis University.
He completed a neuropsychology specialty track internship at the Memphis VA Medical Center and Semmes Murphey Neurologic & Spine Institute and a post-doctoral fellowship at Emory University School of Medicine. He has authored/co-authored several peer-reviewed publications and presentations. He is fluent in German and Romanian.
At NeuroCog Trials Dr. Stroescu oversees the data quality, validity, and the training processes for several widely used clinical and cognitive measures, including the ADAS-cog, ADCS-CGIC, ADCS-ADL, MMSE, and other neurocognitive tests. He also serves as an internal consultant for neuropsychological indications in neurologic disorders.
Dr. Khan serves as a Sr. Biostatistician, overseeing statistical and psychometric analysis. She has over 15 years of experience in clinical trials, psychometrics, testing and measurement, and statistical analysis in CNS Trials. She has served as a statistical and psychometric lead in Clinical Data Sciences at eCOA and Rater Training vendors where she has developed processes for clinical data validation, and implemented statistical methods for developing and testing rater training methodologies, clinical algorithms and data surveillance techniques.
Dr. Khan is a former American Society of Clinical Psychopharmacology (ASCP) New Investigator Award recipient, International Congress of Schizophrenia Research (ICOSR) Young Investigator Award recipient and European Psychiatric Association (EPA) Travel Award recipient, and has recently completed a 5-year research grant from the US NIH to assess the relationship of genotypes and response to cognitive interventions. She has co-authored over 50 peer-reviewed publications and has contributed to book chapters and review articles on schizophrenia, Alzheimer’s, Autism, and other mental health areas.
Dr. Khan has received her BA at SUNY Stony Brook, an MA at SUNY Albany, and her MS and PhD from Fordham University. Her training is in statistics with a focus on psychometric and Bayesian applications in clinical trials. She continues to hold an appointment at Nathan S. Kline Institute for Psychiatric Research in Orangeburg, NY in the Psychopharmacology Research Program.